BACKGROUND: Angiogenesis, the formation of new blood vessels from the endothelium of the existing vasculature, describes a crucial process in tumor growth, disease progression, and metastasis. Therefore, the upcoming strategy of inhibiting tumor angiogenesis has generated different treatment modalities, which have been transferred into clinical practice in recent years. Currently, this concept is applied to target the vasculature of different visceral tumors and intensive clinical research has just started. MATERIALS AND METHODS: This review summarizes the modifications of systemic treatment of visceral tumors by targeting the vasculature in the past years. Moreover, novel targets and treatment strategies will be discussed to evaluate future directions. RESULTS: Leading antiangiogenic drugs combined with systemic chemotherapy have been applied with increasing success during the last years. Therefore, the concept of combining vascular targeting agents with established chemotherapeutic regimens has been increasingly adopted into the therapies of different visceral tumors. CONCLUSION: Targeting the vasculature of visceral tumors in combination with established standard tumor therapies includes major clinical potential for future therapy concepts.
BACKGROUND: Angiogenesis, the formation of new blood vessels from the endothelium of the existing vasculature, describes a crucial process in tumor growth, disease progression, and metastasis. Therefore, the upcoming strategy of inhibiting tumor angiogenesis has generated different treatment modalities, which have been transferred into clinical practice in recent years. Currently, this concept is applied to target the vasculature of different visceral tumors and intensive clinical research has just started. MATERIALS AND METHODS: This review summarizes the modifications of systemic treatment of visceral tumors by targeting the vasculature in the past years. Moreover, novel targets and treatment strategies will be discussed to evaluate future directions. RESULTS: Leading antiangiogenic drugs combined with systemic chemotherapy have been applied with increasing success during the last years. Therefore, the concept of combining vascular targeting agents with established chemotherapeutic regimens has been increasingly adopted into the therapies of different visceral tumors. CONCLUSION: Targeting the vasculature of visceral tumors in combination with established standard tumor therapies includes major clinical potential for future therapy concepts.
Authors: M Zweifel; G C Jayson; N S Reed; R Osborne; B Hassan; J Ledermann; G Shreeves; L Poupard; S-P Lu; J Balkissoon; D J Chaplin; G J S Rustin Journal: Ann Oncol Date: 2011-01-27 Impact factor: 32.976
Authors: Sergio Li Calzi; Matthew B Neu; Lynn C Shaw; Jennifer L Kielczewski; Nicanor I Moldovan; Maria B Grant Journal: Microvasc Res Date: 2010-02-25 Impact factor: 3.514
Authors: Jianzhong Huang; Samuel Z Soffer; Eugene S Kim; Kimberly W McCrudden; Joe Huang; Tamara New; Christina A Manley; William Middlesworth; Kathleen O'Toole; Darrell J Yamashiro; Jessica J Kandel Journal: Mol Cancer Res Date: 2004-01 Impact factor: 5.852
Authors: James Cassidy; Leonard B Saltz; Bruce J Giantonio; Fairooz F Kabbinavar; Herbert I Hurwitz; Ulrich-Peter Rohr Journal: J Cancer Res Clin Oncol Date: 2009-11-11 Impact factor: 4.553
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Amit Nair; Nicola Ingram; Eldo T Verghese; Imeshi Wijetunga; Alexander F Markham; Judy Wyatt; K Rajendra Prasad; P Louise Coletta Journal: Cell Oncol (Dordr) Date: 2020-05-28 Impact factor: 6.730